Navigation Links
San Francisco City Hall Turns Pink, Draws Attention to Disparities in Breast Cancer Screening, Treatment
Date:1/10/2008

rea Affiliate

Assemblywoman Fiona Ma

Other elected officials (invited)

WHEN: Friday, January 11, 2008

5:30 p.m. (City Hall will stay lit until morning)

WHERE: San Francisco City Hall Steps

1 Dr CB Goodlett Place


'/>"/>
SOURCE Susan G. Komen for the Cure
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. HCV and HBV spreading more slowly among injection drug users in San Francisco
2. San Francisco Psoriasis Event Tonight Will Celebrate First National Short Sleeve Day
3. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
4. ABC TV San Francisco Features Canine Cancer Research Story: Saving Our Dogs, Helping Humans Beat Cancer - Work at Morris Animal Foundation, UC-Davis
5. The era of global aging: GSA showcases cutting-edge San Francisco meeting topics
6. San Francisco Bay Area Autism Speaks Chapter Endorses Blue Ribbon Commission on Autism Recommendations for Equitable Insurance Coverage for Children With Autism
7. Press briefings to address longevity, mobility, brain fitness at GSAs San Francisco meeting
8. Hooray for the Bay! San Francisco Officially Named Best Place to Leave Your Heart...and Keep Your Health
9. Run-in-a-Million Run from San Francisco to Los Angeles to Raise Awareness About AIDS and HIV Testing
10. BBVA Chairman Francisco González announces the BBVA Frontiers of Knowledge Awards
11. Photo: Two Men Raising Awareness of HIV/AIDS by Running Minimum of a Marathon a Day from San Francisco to Los Angeles
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 1NASA Research Reveals Major Insight Into Evolution of Life on Earth 4870 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 1The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 2The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 3The CDC and Lysol Partner to Educate Kids About How to Help Protect Themselves From Harmful Germs 54897 4Patch Shots May Someday Replace Injections 54893 1Patch Shots May Someday Replace Injections 54893 2
Other Medicine Technology:New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 2New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 3New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 4New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 5New Analysis of METEOR Study Demonstrate Effects of AstraZeneca's CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 2SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 3SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 4SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 5SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 6SCH 530348 (TRA), a Novel Investigational Antiplatelet Agent, Shown to Inhibit Platelet Aggregation in PCI Patients 7